Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?

Given the wide spectrum of unique characteristics of macular neovascularization type 3 (MNV3) compared with types 1 and 2, we suggest regrading the colour photography assessment of the AREDS study to verify the impact of AREDS supplements on eyes with MNV3.

Automated summary

Considering the unique characteristics of MNV3 compared to types 1 and 2, reevaluating the color photography assessment in the AREDS study is suggested to determine the impact of AREDS supplements on eyes with MNV3.